NASDAQ:PCRXPacira Biosciences Stock Price, Forecast & News

Pacira Biosciences' stock was trading at $35.19 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, PCRX stock has increased by 26.9% and is now trading at $44.65. View which stocks have been most impacted by Coronavirus.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Biosciences in the last year. There are currently 5 hold ratings and 10 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Pacira Biosciences.

Pacira Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Pacira Biosciences.

Pacira Biosciences Inc (NASDAQ:PCRX) released its earnings results on Thursday, May, 7th. The company reported $0.53 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.30 by $0.23. The business had revenue of $105.68 million for the quarter, compared to the consensus estimate of $101.64 million. Pacira Biosciences had a negative net margin of 0.02% and a positive return on equity of 13.89%. The business's revenue was up 15.7% on a year-over-year basis. During the same quarter last year, the company posted $0.22 earnings per share. View Pacira Biosciences' earnings history.

15 Wall Street analysts have issued twelve-month target prices for Pacira Biosciences' stock. Their forecasts range from $41.00 to $85.00. On average, they anticipate Pacira Biosciences' stock price to reach $54.50 in the next year. This suggests a possible upside of 22.1% from the stock's current price. View analysts' price targets for Pacira Biosciences.

Press coverage about PCRX stock has been trending somewhat positive recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Pacira Biosciences earned a news sentiment score of 1.8 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutPacira Biosciences.

Some companies that are related to Pacira Biosciences include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Pacira Biosciences investors own include Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Celgene (CELG), Clovis Oncology (CLVS), NVIDIA (NVDA), Bausch Health Companies (BHC), Exelixis (EXEL), Micron Technology (MU), Incyte (INCY) and Neurocrine Biosciences (NBIX).

Pacira Biosciences trades on the NASDAQ under the ticker symbol "PCRX."

Pacira Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (3.35%), State Street Corp (3.33%), Spyglass Capital Management LLC (2.83%), Clearbridge Investments LLC (2.67%), Frontier Capital Management Co. LLC (2.57%) and Schroder Investment Management Group (1.94%). Company insiders that own Pacira Biosciences stock include Andreas Wicki, Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, Gary W Pace, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Paul J Hastings, Richard Scranton and Roy Winston. View institutional ownership trends for Pacira Biosciences.

PCRX stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Two Sigma Investments LP, Schroder Investment Management Group, Nuveen Asset Management LLC, Maverick Capital Ltd., Maverick Capital Ltd., Two Sigma Advisers LP, and UBS Group AG. Company insiders that have sold Pacira Biosciences company stock in the last year include Charles A Reinhart III, Charles Anthony Laranjeira, David M Stack, Dennis Mcloughlin, John P Phd Longenecker, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings, and Richard Scranton. View insider buying and selling activity for Pacira Biosciences.

PCRX stock was purchased by a variety of institutional investors in the last quarter, including Spyglass Capital Management LLC, Loomis Sayles & Co. L P, Rice Hall James & Associates LLC, State Street Corp, Russell Investments Group Ltd., Mesirow Financial Investment Management Equity Management, Granahan Investment Management Inc. MA, and Grantham Mayo Van Otterloo & Co. LLC. Company insiders that have bought Pacira Biosciences stock in the last two years include Gary W Pace, Mark A Kronenfeld, and Roy Winston. View insider buying and selling activity for Pacira Biosciences.

Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of PCRX stock can currently be purchased for approximately $44.65.

Pacira Biosciences has a market capitalization of $1.88 billion and generates $421.03 million in revenue each year. The company earns $-11,020,000.00 in net income (profit) each year or $0.86 on an earnings per share basis. Pacira Biosciences employs 518 workers across the globe.

The official website for Pacira Biosciences is www.pacira.com.

Pacira Biosciences' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]